ZIYAD A AYYOUB
- Type
- Physician · Allopathic & Osteopathic Physicians / Physical Medicine & Rehabilitation
- Where
- PARAMOUNT, CA
- NPI
- 1356451579
- Received
- $323,126 in 428 records, 2019 to 2025 ($321,630 general, $1,496 research)
- As principal investigator
- $1,430,426 of research payments to others in 4,301 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 22 | $22,398 |
| 2024 | General payment | 65 | $37,561 |
| 2024 | Research payment | 3 | $1,496 |
| 2023 | General payment | 68 | $47,457 |
| 2022 | General payment | 48 | $47,015 |
| 2021 | General payment | 47 | $62,466 |
| 2020 | General payment | 34 | $28,366 |
| 2019 | General payment | 141 | $76,364 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| ABBVIE INC. | 105 | $92,783 | 2022–2025 |
| Allergan, Inc. | 89 | $92,172 | 2019–2022 |
| Ipsen Biopharmaceuticals, Inc | 59 | $68,504 | 2019–2024 |
| MERZ NORTH AMERICA, INC. | 42 | $30,243 | 2019–2020 |
| MDD US Operations, LLC | 52 | $16,794 | 2019–2023 |
| Merz Pharmaceuticals, LLC | 37 | $7,250 | 2021–2025 |
| Ipsen Innovation | 5 | $5,734 | 2020 |
| Ipsen Biopharm Limited | 1 | $4,380 | 2021 |
| Pacira Pharmaceuticals Incorporated | 16 | $2,183 | 2023–2024 |
| Ipsen Pharma SAS | 5 | $1,913 | 2019–2022 |
| Nevro Corp. | 10 | $721 | 2019 |
| REVANCE THERAPEUTICS, INC. | 2 | $262 | 2024 |
| Lundbeck LLC | 2 | $122 | 2025 |
| Novo Nordisk Inc | 2 | $37 | 2023 |
| Medtronic USA, Inc. | 1 | $20 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 70 | $210,029 |
| Consulting Fee | 29 | $47,458 |
| Honoraria | 13 | $29,795 |
| Travel and Lodging | 72 | $20,232 |
| Food and Beverage | 238 | $13,943 |
| Research payment | 3 | $1,496 |
| Education | 3 | $171 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | ABBVIE INC. | $1,400 | Consulting Fee | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-12-11 | ABBVIE INC. | $5,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-09-25 | ABBVIE INC. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-09-10 | Lundbeck LLC | $62 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-09-10 | Lundbeck LLC | $59 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-08-21 | ABBVIE INC. | $3,850 | Consulting Fee | Cash or cash equivalent | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-08-21 | ABBVIE INC. | $1,050 | Consulting Fee | Cash or cash equivalent | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-08-21 | ABBVIE INC. | $466 | Consulting Fee | Cash or cash equivalent | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-07-17 | Merz Pharmaceuticals, LLC | $149 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2025 | |
| 2025-06-28 | ABBVIE INC. | $111 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-06-28 | ABBVIE INC. | $66 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-06-28 | ABBVIE INC. | $57 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-06-28 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-06-27 | ABBVIE INC. | $466 | Travel and Lodging | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-06-27 | ABBVIE INC. | $299 | Travel and Lodging | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-06-24 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-05-16 | ABBVIE INC. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-05-12 | ABBVIE INC. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-04-07 | ABBVIE INC. | $5,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-20 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-01-21 | ABBVIE INC. | $102 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-01-07 | ABBVIE INC. | $525 | Consulting Fee | Cash or cash equivalent | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2024-12-19 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-12-18 | Merz Pharmaceuticals, LLC | $38 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-12-17 | ABBVIE INC. | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-12-17 | ABBVIE INC. | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-12-05 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-12-03 | ABBVIE INC. | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-11-21 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-14 | Merz Pharmaceuticals, LLC | $4 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-11-13 | Merz Pharmaceuticals, LLC | $19 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-11-09 | Merz Pharmaceuticals, LLC | $89 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-11-09 | Merz Pharmaceuticals, LLC | $46 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-11-08 | Merz Pharmaceuticals, LLC | $37 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-11-07 | ABBVIE INC. | $57 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-07 | ABBVIE INC. | $42 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-06 | Pacira Pharmaceuticals Incorporated | $124 | Food and Beverage | In-kind items and services | Iovera Device, Pain Management | 2024 | |
| 2024-10-24 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-10-24 | Ipsen Biopharmaceuticals, Inc | $13 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2024 | |
| 2024-08-15 | Merz Pharmaceuticals, LLC | $28 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-08-15 | Merz Pharmaceuticals, LLC | $10 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-07-25 | Merz Pharmaceuticals, LLC | $127 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-07-25 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-07-16 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-07-09 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-07-09 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-07-09 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-06-26 | Ipsen Biopharmaceuticals, Inc | $8 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2024 | |
| 2024-06-13 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-06-08 | ABBVIE INC. | $31 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-06-08 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-06-07 | ABBVIE INC. | $474 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-06-07 | ABBVIE INC. | $57 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-06-07 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-06-06 | ABBVIE INC. | $81 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-06-01 | Ipsen Biopharmaceuticals, Inc | $4,515 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Dysport Drug, Neurology | 2024 | |
| 2024-06-01 | Ipsen Biopharmaceuticals, Inc | $25 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2024 | |
| 2024-05-30 | Ipsen Biopharmaceuticals, Inc | $6 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2024 | |
| 2024-05-08 | REVANCE THERAPEUTICS, INC. | $137 | Food and Beverage | In-kind items and services | DAXI Drug, AESTHETICS AND THERAPEUTICS | 2024 | |
| 2024-04-24 | ABBVIE INC. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-04-24 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-04-03 | Ipsen Biopharmaceuticals, Inc | $6 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2024 | |
| 2024-03-25 | REVANCE THERAPEUTICS, INC. | $124 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2024 | |
| 2024-03-23 | ABBVIE INC. | $357 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-23 | ABBVIE INC. | $329 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-23 | ABBVIE INC. | $120 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-23 | ABBVIE INC. | $70 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-23 | ABBVIE INC. | $60 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-23 | ABBVIE INC. | $58 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-23 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-23 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-22 | ABBVIE INC. | $150 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-22 | ABBVIE INC. | $53 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-03-22 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-03-22 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-03-20 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-03-12 | ABBVIE INC. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-02-10 | Ipsen Biopharmaceuticals, Inc | $1,935 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Dysport Drug, Neurology | 2024 | |
| 2024-02-03 | Pacira Pharmaceuticals Incorporated | $62 | Food and Beverage | In-kind items and services | Zilretta Drug, Pain Management | 2024 | |
| 2024-02-03 | Pacira Pharmaceuticals Incorporated | $30 | Travel and Lodging | Cash or cash equivalent | Zilretta Drug, Pain Management | 2024 | |
| 2024-02-03 | Pacira Pharmaceuticals Incorporated | $23 | Food and Beverage | In-kind items and services | Zilretta Drug, Pain Management | 2024 | |
| 2024-02-02 | Pacira Pharmaceuticals Incorporated | $769 | Travel and Lodging | In-kind items and services | Zilretta Drug, Pain Management | 2024 | |
| 2024-02-02 | Pacira Pharmaceuticals Incorporated | $127 | Travel and Lodging | In-kind items and services | Zilretta Drug, Pain Management | 2024 | |
| 2024-02-02 | Pacira Pharmaceuticals Incorporated | $104 | Food and Beverage | In-kind items and services | Zilretta Drug, Pain Management | 2024 | |
| 2024-02-02 | Pacira Pharmaceuticals Incorporated | $30 | Travel and Lodging | Cash or cash equivalent | Zilretta Drug, Pain Management | 2024 | |
| 2024-02-02 | Pacira Pharmaceuticals Incorporated | $27 | Food and Beverage | Cash or cash equivalent | Zilretta Drug, Pain Management | 2024 | |
| 2024-01-22 | Merz Pharmaceuticals, LLC | $932 | Research payment | Cash or cash equivalent | Xeomin Biological, Musculoskeletal | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-01-12 | Merz Pharmaceuticals, LLC | $294 | Research payment | Cash or cash equivalent | Xeomin Biological, Musculoskeletal | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-01-12 | Merz Pharmaceuticals, LLC | $269 | Research payment | Cash or cash equivalent | Xeomin Biological, Musculoskeletal | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-01-03 | Merz Pharmaceuticals, LLC | $17 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2024 | |
| 2023-12-21 | ABBVIE INC. | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-12-21 | ABBVIE INC. | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-12-01 | Merz Pharmaceuticals, LLC | $49 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-11-29 | Ipsen Biopharmaceuticals, Inc | $128 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-21 | ABBVIE INC. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-11-17 | ABBVIE INC. | $110 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-11-17 | Merz Pharmaceuticals, LLC | $38 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-11-16 | Ipsen Biopharmaceuticals, Inc | $86 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-11-16 | Pacira Pharmaceuticals Incorporated | $82 | Food and Beverage | In-kind items and services | Iovera Device, Pain Management | 2023 | |
| 2023-11-15 | Ipsen Biopharmaceuticals, Inc | $133 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-11-08 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-10-21 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-10-04 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-27 | Ipsen Biopharmaceuticals, Inc | $5 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-09-07 | Merz Pharmaceuticals, LLC | $12 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-08-31 | Merz Pharmaceuticals, LLC | $150 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-08-24 | Ipsen Biopharmaceuticals, Inc | $4,515 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Dysport Drug, Neurology | 2023 | |
| 2023-08-24 | Ipsen Biopharmaceuticals, Inc | $52 | Travel and Lodging | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-08-24 | Ipsen Biopharmaceuticals, Inc | $48 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-08-23 | ABBVIE INC. | $98 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-08-23 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-08-22 | ABBVIE INC. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-08-10 | Merz Pharmaceuticals, LLC | $72 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-08-02 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-29 | ABBVIE INC. | $585 | Travel and Lodging | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-29 | ABBVIE INC. | $484 | Travel and Lodging | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-29 | ABBVIE INC. | $65 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-29 | ABBVIE INC. | $56 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-29 | ABBVIE INC. | $28 | Travel and Lodging | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-29 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-28 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-28 | ABBVIE INC. | $53 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-28 | ABBVIE INC. | $40 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-28 | ABBVIE INC. | $25 | Travel and Lodging | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-07-20 | MDD US Operations, LLC | $880 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MYOBLOC Drug, NEUROLOGY | 2023 | |
| 2023-07-05 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-06-28 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-06-21 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-06-17 | Pacira Pharmaceuticals Incorporated | $127 | Travel and Lodging | In-kind items and services | Iovera Device, Pain Management | 2023 | |
| 2023-06-17 | Pacira Pharmaceuticals Incorporated | $21 | Food and Beverage | In-kind items and services | Iovera Device, Pain Management | 2023 | |
| 2023-06-17 | Pacira Pharmaceuticals Incorporated | $8 | Food and Beverage | In-kind items and services | Iovera Device, Pain Management | 2023 | |
| 2023-06-16 | Pacira Pharmaceuticals Incorporated | $508 | Travel and Lodging | In-kind items and services | Iovera Device, Pain Management | 2023 | |
| 2023-06-16 | Pacira Pharmaceuticals Incorporated | $102 | Food and Beverage | In-kind items and services | Iovera Device, Pain Management | 2023 | |
| 2023-06-02 | ABBVIE INC. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-05-03 | Merz Pharmaceuticals, LLC | $19 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-05-01 | ABBVIE INC. | $2,100 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-03-30 | Merz Pharmaceuticals, LLC | $45 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-03-29 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-03-15 | Pacira Pharmaceuticals Incorporated | $32 | Food and Beverage | In-kind items and services | Iovera Device, Pain Management | 2023 | |
| 2023-03-07 | Ipsen Biopharmaceuticals, Inc | $3,870 | Honoraria | Cash or cash equivalent | Dysport Drug, Neurology | 2023 | |
| 2023-03-07 | Ipsen Biopharmaceuticals, Inc | $359 | Travel and Lodging | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-03-07 | Ipsen Biopharmaceuticals, Inc | $103 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-03-07 | Ipsen Biopharmaceuticals, Inc | $80 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Dysport Drug, Neurology | 2023 | |
| 2023-02-24 | ABBVIE INC. | $65 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-02-23 | Merz Pharmaceuticals, LLC | $172 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-02-23 | Ipsen Biopharmaceuticals, Inc | $140 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-02-22 | Merz Pharmaceuticals, LLC | $75 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-02-22 | Merz Pharmaceuticals, LLC | $24 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-02-22 | Merz Pharmaceuticals, LLC | $8 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2023 | |
| 2023-02-06 | ABBVIE INC. | $1,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-02-06 | ABBVIE INC. | $1,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2023 | |
| 2023-02-05 | Ipsen Biopharmaceuticals, Inc | $10,965 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Dysport Drug, Neurology | 2023 | |
| 2023-02-05 | Ipsen Biopharmaceuticals, Inc | $1,053 | Travel and Lodging | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-02-05 | Ipsen Biopharmaceuticals, Inc | $588 | Travel and Lodging | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-02-05 | Ipsen Biopharmaceuticals, Inc | $401 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-01-01 | Ipsen Biopharmaceuticals, Inc | $889 | Travel and Lodging | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-01-01 | Ipsen Biopharmaceuticals, Inc | $588 | Travel and Lodging | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2023-01-01 | Ipsen Biopharmaceuticals, Inc | $401 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2023 | |
| 2022-10-22 | Ipsen Biopharmaceuticals, Inc | $89 | Food and Beverage | In-kind items and services | DYSPORT Drug, Neurology | 2022 | |
| 2022-10-21 | Merz Pharmaceuticals, LLC | $5 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2022 | |
| 2022-10-20 | Ipsen Biopharmaceuticals, Inc | $37 | Food and Beverage | In-kind items and services | DYSPORT Drug, Neurology | 2022 | |
| 2022-10-19 | ABBVIE INC. | $93 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2022 | |
| 2022-09-14 | Merz Pharmaceuticals, LLC | $67 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2022 | |
| 2022-09-01 | ABBVIE INC. | $525 | Consulting Fee | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | 2022 | |
| 2022-08-20 | ABBVIE INC. | $90 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-20 | ABBVIE INC. | $72 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-20 | ABBVIE INC. | $56 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-20 | ABBVIE INC. | $39 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-20 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-19 | ABBVIE INC. | $7,481 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-19 | ABBVIE INC. | $3,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-19 | ABBVIE INC. | $630 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-19 | ABBVIE INC. | $397 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-19 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-19 | ABBVIE INC. | $74 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-19 | ABBVIE INC. | $39 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-19 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-08-18 | ABBVIE INC. | $40 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-07-28 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2022 | |
| 2022-07-08 | Merz Pharmaceuticals, LLC | $2,925 | Consulting Fee | Cash or cash equivalent | Xeomin Biological, Musculoskeletal | 2022 | |
| 2022-06-08 | Merz Pharmaceuticals, LLC | $60 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2022 | |
| 2022-04-30 | Ipsen Pharma SAS | $751 | Travel and Lodging | In-kind items and services | DYSPORT Drug, Neurology | 2022 | |
| 2022-04-30 | Ipsen Pharma SAS | $270 | Food and Beverage | In-kind items and services | DYSPORT Drug, Neurology | 2022 | |
| 2022-04-28 | ABBVIE INC. | $3,840 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-04-28 | Allergan, Inc. | $19 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2022 | |
| 2022-04-14 | ABBVIE INC. | $3,840 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-04-14 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2022 | |
| 2022-04-14 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2022 | |
| 2022-04-13 | Merz Pharmaceuticals, LLC | $104 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2022 | |
| 2022-03-29 | Ipsen Biopharmaceuticals, Inc | $4,515 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DYSPORT Drug, Neurology | 2022 | |
| 2022-03-29 | Ipsen Biopharmaceuticals, Inc | $130 | Food and Beverage | In-kind items and services | DYSPORT Drug, Neurology | 2022 | |
| 2022-03-29 | Ipsen Biopharmaceuticals, Inc | $61 | Travel and Lodging | In-kind items and services | DYSPORT Drug, Neurology | 2022 | |
| 2022-03-29 | Merz Pharmaceuticals, LLC | $43 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2022 | |
| 2022-03-10 | Allergan, Inc. | $3,840 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-03-10 | Ipsen Biopharmaceuticals, Inc | $1,290 | Consulting Fee | Cash or cash equivalent | DYSPORT Drug, Neurology | 2022 | |
| 2022-03-10 | Allergan, Inc. | $21 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2022 | |
| 2022-03-03 | Merz Pharmaceuticals, LLC | $46 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2022 | |
| 2022-02-16 | Allergan, Inc. | $3,840 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2022 | |
| 2022-02-16 | Allergan, Inc. | $18 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2022 | |
| 2022-02-08 | Allergan, Inc. | $2 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2022 |
The latest 200 records of 428.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-18 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $1,962 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-12-18 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $1,962 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-12-16 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $262 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-12-12 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $1,962 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-11-26 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $2,944 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-11-25 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $2,944 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-11-17 | Merz Pharmaceuticals, LLC | RANCHO RESEARCH INSTITUTE | $35,733 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-11-17 | Merz Pharmaceuticals, LLC | RANCHO RESEARCH INSTITUTE | $4,151 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-11-14 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $524 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-11-04 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $13 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-10-30 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $17 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-10-21 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $1,962 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-10-16 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $981 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-10-16 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $981 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-09-17 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $32 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-09-05 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $981 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-08-13 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $981 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-08-12 | Ipsen Innovation | RANCHO RESEARCH INSTITUTE | $8,004 | An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dos | 2025 |
| 2025-08-11 | Merz Pharmaceuticals, LLC | RANCHO RESEARCH INSTITUTE | $88,401 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-06-18 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $11,411 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-05-07 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $338 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $2,926 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $524 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $13 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $5,816 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $43 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $34 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $1,962 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $3,925 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-22 | Pacira Pharmaceuticals Incorporated | RANCHO RESEARCH INSTITUTE | $32 | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in S | 2025 |
| 2025-04-10 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $20,831 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-04-10 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $6,028 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-03-18 | ABBVIE INC. | RANCHO RESEARCH INSTITUTE INC | $5,250 | M23-499 - Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult | 2025 |
| 2025-03-01 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $6,024 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-02-17 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $2,547 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-02-10 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $40,652 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2025-01-06 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $30,134 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2025 |
| 2024-12-31 | ABBVIE INC. | RANCHO RESEARCH INSTITUTE | $19,516 | M23-499 Ph 2 Spasticity | 2024 |
| 2024-12-09 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $13,952 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-11-12 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $1,566 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-10-07 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $6,971 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-09-16 | Merz Pharmaceuticals, LLC | RANCHO RESEARCH INSTITUTE | $956 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-09-11 | Merz Pharmaceuticals, LLC | RANCHO RESEARCH INSTITUTE | $14,987 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-08-02 | ABBVIE INC. | RANCHO RESEARCH INSTITUTE INC | $3,192 | Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participa | 2024 |
| 2024-07-15 | Merz Pharmaceuticals, LLC | RANCHO RESEARCH INSTITUTE | $6,852 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-07-05 | ABBVIE INC. | RANCHO RESEARCH INSTITUTE INC | $8,634 | Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participa | 2024 |
| 2024-07-01 | Merz Pharmaceuticals, LLC | RANCHO RESEARCH INSTITUTE | $5,533 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-07-01 | Merz Pharmaceuticals, LLC | RANCHO RESEARCH INSTITUTE | $4,442 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-05-20 | Merz Pharmaceuticals, LLC | Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center | $20,500 | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2024 |
| 2024-04-30 | Supernus Pharmaceuticals, Inc. | RANCHO RESEARCH INSTITUTE | $3,000 | A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MY | 2024 |
| 2024-04-30 | Supernus Pharmaceuticals, Inc. | RANCHO RESEARCH INSTITUTE | $1,200 | A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MY | 2024 |
| 2024-04-30 | Supernus Pharmaceuticals, Inc. | RANCHO RESEARCH INSTITUTE | $1,200 | A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MY | 2024 |
| 2024-04-30 | Supernus Pharmaceuticals, Inc. | RANCHO RESEARCH INSTITUTE | $3,000 | A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MY | 2024 |
| 2024-04-30 | Supernus Pharmaceuticals, Inc. | RANCHO RESEARCH INSTITUTE | $1,200 | A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MY | 2024 |
| 2024-03-20 | Ipsen Pharma SAS | RANCHO RESEARCH INSTITUTE | $3,127 | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-03-20 | Ipsen Pharma SAS | RANCHO RESEARCH INSTITUTE | $3,127 | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-02-02 | ABBVIE INC. | RANCHO RESEARCH INSTITUTE INC | $15,000 | Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participa | 2024 |
| 2023-12-31 | ABBVIE INC. | RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER | $348 | Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participa | 2023 |
| 2023-12-07 | Ipsen Innovation | RANCHO RESEARCH INSTITUTE | $937 | ArmA | 2023 |
| 2023-12-01 | Ipsen Innovation | RANCHO RESEARCH INSTITUTE | $22,656 | ArmA | 2023 |
| 2023-08-15 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE | $1,166 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-08-15 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE | $1,166 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-08-15 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE | $1,166 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $225 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $225 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $276 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $276 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $303 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $303 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $276 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $276 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $33 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $33 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $276 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $276 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $47 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $47 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $67 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $67 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $47 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $47 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $112 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $47 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $47 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $303 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $303 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $142 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $142 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $60 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $60 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $106 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $106 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $33 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $33 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $106 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $106 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $33 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $33 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $47 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
| 2023-06-27 | MDD US Operations, LLC | RANCHO RESEARCH INSTITUTE INC | $47 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MY | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Paramount, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Paramount, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 52,050 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 53,733 | 10,014,009 | 39,538,223 |
| Median age B01002 | 33.4 | 38.2 | 37.9 |
| Under 18 B01001 | 25.1% | 20.6% | 22.0% |
| 65 and over B01001 | 10.1% | 15.2% | 15.7% |
| Households B11001 | 14,618 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 36.4% | 33.4% | 27.0% |
| Median household income B19013 | $75,250 | $90,112 | $99,122 |
| Median family income B19113 | $79,617 | $101,573 | $113,346 |
| Per capita income B19301 | $26,819 | $45,792 | $49,513 |
| Poverty rate B17001 | 12.6% | 13.7% | 12.0% |
| Unemployment rate B23025 | 5.7% | 7.3% | 6.6% |
| Civilian labor force B23025 | 26,853 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 28.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 14.9% | 36.0% | 37.1% |
| Housing units B25001 | 14,773 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 43.0% | 45.9% | 55.9% |
| Renters B25003 | 57.0% | 54.1% | 44.1% |
| Median home value B25077 | $533,700 | $834,200 | $734,700 |
| Median gross rent B25064 | $1,875 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 4.1% | 24.7% | 33.8% |
| Black B03002 | 9.2% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 81.3% | 48.4% | 40.2% |
| Asian B03002 | 3.7% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Paramount, CA.
Comments